Top Page
Peijia Medical Ltd.
(Frankfurt:9996)
Peijia Medical Ltd. (9996) vs. iShares MSCI Hong Kong ETF (EWH)
Peijia Medical Ltd. Business Overview & Revenue Model
Peijia Medical Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 615.48M | 441.13M | 250.83M | 136.53M | 38.66M |
| Gross Profit | 433.62M | 325.37M | 176.20M | 95.65M | 25.22M |
| EBITDA | -192.93M | -348.52M | -359.90M | -546.54M | -190.87M |
| Net Income | -226.58M | -392.52M | -407.81M | -574.22M | -2.07B |
Balance Sheet | |||||
| Total Assets | 2.69B | 2.67B | 3.32B | 3.16B | 2.88B |
| Cash, Cash Equivalents and Short-Term Investments | 712.52M | 942.92M | 1.74B | 2.30B | 2.46B |
| Total Debt | 253.40M | 221.13M | 131.88M | 7.63M | 9.13M |
| Total Liabilities | 644.11M | 397.88M | 678.86M | 144.48M | 67.99M |
| Stockholders Equity | 2.03B | 2.27B | 2.64B | 3.02B | 2.81B |
Cash Flow | |||||
| Free Cash Flow | -285.29M | -899.67M | -506.61M | -506.11M | -206.35M |
| Operating Cash Flow | -5.18M | -583.49M | -376.20M | -436.37M | -181.10M |
| Investing Cash Flow | -140.38M | -386.29M | -463.28M | -424.75M | -12.48M |
| Financing Cash Flow | 10.38M | 85.11M | 117.44M | 741.98M | 2.34B |
Peijia Medical Ltd. Technical Analysis
Peijia Medical Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% | |
51 Neutral | HK$4.27B | ― | -10.43% | ― | 36.76% | 42.89% | |
| $2.03B | ― | -31.45% | ― | ― | ― | ||
| €741.15M | 53.77 | 3.22% | ― | ― | ― | ||
74 Outperform | HK$7.44B | 26.73 | 15.22% | 2.52% | 12.48% | 71.75% | |
65 Neutral | HK$6.53B | 32.03 | 4.39% | 3.18% | -32.05% | -54.47% | |
47 Neutral | HK$2.12B | ― | -2.19% | ― | 5.32% | 89.43% |
Peijia Medical Ltd. Corporate Events
Peijia Medical Ltd. announced that all resolutions proposed at its Annual General Meeting on May 27, 2025, were passed. These resolutions included the adoption of financial statements, re-election of directors, appointment of auditors, and granting of mandates to the board for share issuance and repurchase. The successful passage of these resolutions supports the company’s governance and operational strategies, potentially strengthening its market position and reassuring stakeholders of its stable management.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. announced the grant of 1,439,400 share options to eligible employees under its Share Option Scheme. This initiative is designed to incentivize employees, with a vesting period spread over three years and performance targets tied to appraisals, potentially enhancing employee retention and aligning staff interests with company growth.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. has announced its upcoming annual general meeting scheduled for May 27, 2025, in Suzhou, China. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, appointment of Deloitte Touche Tohmatsu as auditor, and authorization for the board to manage share capital activities. These decisions are crucial for the company’s governance and strategic direction, potentially impacting its operational efficiency and market positioning.
Peijia Medical Ltd. has announced that its registration application for the TaurusTrio Transcatheter Aortic Valve System has been accepted by the National Medical Products Administration of China. This system, developed under an exclusive license from JenaValve Technology, is intended for patients with severe aortic regurgitation and will benefit from priority review under the NMPA’s Special Review and Approval Procedure for Innovative Medical Devices, potentially enhancing the company’s market position.
Peijia Medical Limited announced that its YonFlow® Flow Diverting Stent has received approval from the National Medical Products Administration of the PRC for its registration application. This stent, developed by Jiangsu NowYon Medical Limited, is notable for being the first globally retrievable flow diverting stent, offering enhanced control during medical procedures. The approval marks a significant step in Peijia Medical’s strategy to expand its product offerings and strengthen its position in the Greater China market, although there is no guarantee of successful commercialization.
Peijia Medical Limited announced the successful completion of the first patient treatment using its ReachTactile™ robotic-assisted TAVR system. This system, which was used in a clinical trial at Xiamen Cardiovascular Hospital, offers a cost-effective and innovative solution for TAVR therapy. It features a modular design that fits conventional catheter rooms, allows for precise operation, and reduces radiation exposure for cardiologists. The system’s remote control capabilities also enable long-distance operations and training, potentially impacting the company’s market position by offering advanced medical solutions.